Crescent Biopharma Balance Sheet
NASDAQ: CBIOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Crescent Biopharma financial position
At the end of fiscal 2025, Crescent Biopharma reported total assets of $240.3 million, up 574.7% from a year earlier against total liabilities of $37.3 million. Shareholders' equity stood at $203.0 million, or 84.5% of assets. The company held $213.2 million in cash and equivalents against $0 of debt, a net cash position of $213.2 million.
The current ratio (current assets divided by current liabilities) was 6.56, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.00.
Summary generated from market data by MetaCap's automated system. Methodology
Crescent Biopharma balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 213.19M | 34.77M | 41.79M | 47.87M | 90.25M | 137.04M | 158.20M | 209.92M | 123.92M | 40.04M |
| Receivables | 18.00M | 0 | — | — | — | — | — | — | — | — |
| Total Current Assets | 236.66M | 34.80M | 43.79M | 50.71M | 90.79M | 138.27M | 162.53M | 212.27M | 127.22M | 40.52M |
| Property, Plant & Equipment | 846.00K | 0 | — | 242.39K | 368.84K | 620.67K | 822.92K | 957.23K | 1.11M | 1.06M |
| Total Assets | 240.29M | 35.62M | 45.32M | 51.81M | 94.35M | 142.83M | 167.97M | 214.84M | 128.58M | 42.39M |
| Accounts Payable | — | 329.30K | 868.12K | 970.19K | 2.11M | 2.09M | 1.44M | 2.66M | 2.65M | 1.57M |
| Total Current Liabilities | 36.07M | 9.61M | 6.84M | 8.88M | 11.82M | 12.43M | 10.95M | 8.76M | 8.17M | 6.33M |
| Long-Term Debt | 0 | 37.48M | — | — | — | — | — | — | — | — |
| Total Liabilities | 37.28M | 47.10M | 6.90M | 8.88M | 12.74M | 14.61M | 13.77M | 9.37M | 8.88M | 7.09M |
| Shareholders' Equity | 203.01M | -15.48M | 38.41M | 42.93M | 81.60M | 128.22M | 154.20M | 205.46M | 119.70M | 35.30M |
| Retained Earnings | -171.81M | -17.87M | -456.49M | -419.59M | -372.90M | -309.47M | -258.44M | -200.55M | -152.28M | -118.98M |
| Total Debt | 0 | 37.48M | — | — | — | — | — | — | — | — |
| Net Cash (Debt) | 213.19M | -2.72M | 41.79M | 47.87M | 90.25M | 137.04M | 158.20M | 209.92M | 123.92M | 40.04M |
| Shares Outstanding | 27.56M | 1.02M | 64.39M | 54.38M | 52.31M | 49.02M | 43.47M | 43.16M | 34.36M | 23.25M |
This table shows 10 annual periods of Crescent Biopharma's balance sheet, from FY 2025 back to FY 2016, across 14 line items including cash & equivalents, receivables, total current assets. Values in USD; B = billions, M = millions. Fiscal periods follow CBIO's reporting calendar. What is a balance sheet?